• Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers
  • The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
  • Two new purpose-built large-scale bioconjugation suites in Lonza’s Ibex® Dedicate Biopark to generate around 180 new jobs, with operations expected to begin in 2026

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today an extension of a long-term collaboration with a major global biopharmaceutical partner. The extended agreement will increase the current dedicated bioconjugation capacity fourfold by adding two new bioconjugation suites for the commercial supply of ADCs at Lonza’s Ibex® Dedicate Biopark in Visp (CH).

The extension will occupy 1500m2 of manufacturing space, and will connect to key infrastructure supporting the containment of highly potent drug linkers and the handling of bioconjugates in a highly automated, high-throughput environment. The two dedicated manufacturing areas are expected to comprise one of the largest bioconjugation facilities globally. The new suites are expected to be operational in 2026 and will generate approximately 180 jobs upon completion.

The announcement expands Lonza’s current relationship with the customer, through which the company provides highly potent payload, drug-linkerconjugation services, and commercial mAb manufacturing from a single site at Visp (CH).

Jean-Christophe Hyvert, President, Biologics, Lonza, commented: “The expansion of this strategic collaboration further validates the concept of Ibex® Solutions and demonstrates our dedication to supporting our partners with operational excellence, specialist expertise and flexible business models. The complete end-to-end ADC ecosystem at our Visp site eliminates supply chain complexities and supports all stages necessary for the manufacture of these highly potent therapies.”

Christian Morello, Vice President, Head of Bioconjugates, Lonza, added: “The expanded relationship with our partner builds upon trust and expertise in delivering manufacturing solutions built upon extensive experience in bringing ADC-based therapies to the clinic and beyond. Our relationship with the customer has been evolving to incorporate all stages of bioconjugate manufacturing. This unique journey is a testament to our dedication, expertise, and production capacity, all helping to advance cancer treatment options.”

ADCs are complex bioconjugates that are typically used for selective targeting of cancer cells. Their unique ability to decrease systemic side effects on healthy cells, while maintaining selective efficacy, brings high commercial and therapeutic potential and is transforming the treatment landscape for cancer patients. ADCs consist of a potent cytotoxic agent, stable linker and a targeting mAb. Lonza has unique experience in supporting ADC manufacturing at a single site, from early development stages to market launch, and manufactures the majority of commercially available ADCs.

Additional Information 

To learn more about Lonza’s Bioconjugation offering, visit: www.lonza.com/biologics/bioconjugates

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Über Lonza Group Ltd.

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our business is structured to meet our customers‘ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 922 million in Half-Year 2023. Find out more at www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Firmenkontakt und Herausgeber der Meldung:

Lonza Group Ltd.
Münchensteinerstraße 38
CH4002 Basel
Telefon: +41 (61) 3168638
Telefax: +41 (61) 3169638
http://www.lonza.com

Ansprechpartner:
Lyle Wheeler
Telefon: +41 (79) 154-9522
E-Mail: lyle.wheeler@lonza.com
Victoria Morgan
Head of Corporate Communications
Telefon: +41 (79) 599-6260
E-Mail: victoria.morgan@lonza.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel